Galectin Therapeutics Inc. announced the appointment of Adam E. Allgood, Pharm.D., R.Ph. as executive director of clinical development, effective immediately. Dr. Allgood most recently was associate director of global pharmaceutical regulatory affairs at UCB Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.62 USD | -1.50% | +0.77% | +57.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.83% | 163M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- GALT Stock
- News Galectin Therapeutics Inc.
- Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development